Stock SVE SYNTHAVERSE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News Synthaverse S.A.

Equities

SVE

PLBMDLB00018

Delayed Warsaw S.E.
Other stock markets
 10:30:39 2024-07-16 am EDT 		5-day change 1st Jan Change
5.46 PLN +0.55% Intraday chart for Synthaverse S.A. +0.55% +27.87%
May. 22 Synthaverse S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 10 Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Synthaverse S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Synthaverse S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Ticker to SVE from BML
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Name to SYNTHAVERSE S.A
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) dropped from S&P Global BMI Index
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
BIOMED-LUBLIN Wytw?rnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 13.398489 million in funding
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Announces Earnings Results for the First Quarter of 2021
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment Arm
CI
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Biomed-Lublin Secures PLN 29.2 Million in EU Financing for Construction of an R&D Center
CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) added to S&P Global BMI Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SVE Stock
  4. News Synthaverse S.A.